The Company's initial launch of Canna-Pet capsules on Amazon will shortly be followed by the availability of Canna-Biscuit dog treats in order to offer the Company's full product lineup of CBD supplements for cats and dogs. All products are available as part of Amazon Prime, offering significant membership advantages and launching an all new and exciting sales channel for the Company and Canna-Pet customers alike.
In related news, the Company is excited to announce Canna-Pet's upcoming release of MaxCBD dog biscuits offering up to six times the CBD of the standard Canna-Biscuit product line. MaxCBD Canna-Biscuits will initially be offered in the highly popular Maple Bacon flavor and will include the Company's "golden ratio" of additional cannabinoids and terpenes for maximum potency without psychoactivity. It is anticipated that the product will initially be available on the Company's website ( www.canna-pet.com) by early April and additional product offerings are planned for this category subject to consumer response.
Company CEO Dr. Soren Mogelsvang States, "We are thrilled to distribute our Canna-Pet products on Amazon. We believe this additional and very important sales channel can offer significant impetus for growth. Of course, we are working on a number of marketing strategies to ensure we maximize the potential of this new opportunity. Among these strategies is the launch of new products, and our new MaxCBD Canna-Biscuit category will be an industry leading test of consumer interest in serving size and ease of use."
About Canna-Pet Products for Pet Health
Canna-Pet offers over-the-counter CBD products for domesticated animals such as cats and dogs. Canna-Pet is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive components. The company uses non-GMO hemp as starting material and all products are proudly made in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet is a leading producer of safe, hemp-based, cannabinoid (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (
Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.
Contact: Peak Pharmaceuticals, Inc. Investor Relations E: email@example.com T: +1 (800) 713-9091 www.peakpharma.com Canna-Pet Support firstname.lastname@example.org www.canna-pet.com